arrow
K

Kaichun Wu

Air Force Medical University教授
H指数:103
被引数:3.7万

个人简介

Dr. Kaichun Wu is a professor and the Deputy Chair of Xijing Hospital of Digestive Diseases, the Fourth Military Medical University. He received his MD & PhD degrees from the Fourth Military Medical University and post-doc training in Nottingham University (UK). He got his research experience in Oxford University(UK), and Northwestern University(USA). He serves as the Vice-President of Chinese Society of Gastroenterology(CSG) and Executive Committee Member of the World Gastroenterology Organisation(WGO) and General Secretary of Asia Pacific Association of Gastroenterology(APAGE). Professor Wu has published more than 300 papers in peer-reviewed journals like Gastroenterology, Hepatology, J Hepatol, Oncogene, J Immunol, FASEB J, Carcinogenesis, Mol Cancer Res, etc. His research work on gastric cancer has received State First Class Award for Science and Technology in China.

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

  1. State First Class Award for Science and Technology in China|China
Efficacy and safety of risankizumab among patients in China with Ulcerative Colitis: A post hoc sub analysis of the randomized phase 2b/3 INSPIRE study

P1004 中国溃疡性结肠炎患者中 risankizumab 的有效性与安全性:INSPIRE 随机 IIb/III 期研究的回顾性亚组分析

2026-01-010
PRE
Shaping the future of probiotics, live biotherapeutic products, and fecal microbiota transplantation: 30 scientific recommendations from the CHINAGUT Conference

塑造益生菌、活体生物疗法产品和粪菌移植的未来:CHINAGUT会议的30项科学建议

iMeta
IF33.2
2025-10-020
OAAI
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Etrasimod作为东亚中度至重度活动性溃疡性结肠炎患者的诱导和维持治疗方案(ENLIGHT UC):一项随机、双盲、安慰剂对照、多中心、III期研究

2025-09-300
PRE
A Novel Score for Predicting Long-Term Outcomes in Recanalisation-Treated Patients With Budd-Chiari Syndrome: A Multicentre Study

一种用于预测接受再通治疗的巴德-奇亚里综合征患者长期预后的新型评分方法:一项多中心研究

2025-08-020
PRE
Rectal diclofenac versus indomethacin for prevention of post-ERCP pancreatitis (DIPPP): a multicentre, double-blind, randomised, controlled trial

直肠双氯芬酸与吲哚美辛预防ERCP后胰腺炎的疗效比较(DIPPP):一项多中心、双盲、随机对照试验

GUT
IF25.8
2025-03-201
PRE
APAGE Position Statements on Green and Sustainability in Gastroenterology, Hepatology, and Gastrointestinal Endoscopy

关于胃肠病学,肝病学和胃肠道内窥镜检查中的绿色和可持续性的APAGE立场声明

2025-01-310
PRE
Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
2025-01-301
OAAI
Etrasimod as induction and maintenance therapy in Asian patients with moderately to severely active Ulcerative Colitis: Results from the maintenance period of a randomised, double-blind, placebo-controlled, multi-centre Phase 3 study (ES101002)
2025-01-220
PRE
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
2024-09-177
PRE